News
NXGLW
0.0599
0.00%
0.0000
NexGel Appoints Ian Blackman as New Chief Financial Officer
TipRanks · 1d ago
Nexgel names Ian Blackman chief financial officer
PUBT · 1d ago
Celularity FY25 operating loss widens to $61.31 million; revenue drops 51% to $26.55 million
PUBT · 1d ago
Analysts Offer Insights on Healthcare Companies: NexGel Inc (NXGL) and Phathom Pharmaceuticals (PHAT)
TipRanks · 1d ago
NEXGEL Names Ian Blackman As CFO
NASDAQ · 4d ago
Nexgel appoints Ian Blackman as CFO
PUBT · 4d ago
*NexGel Appoints Ian Blackman as Chief Fincl Officer >NXGL
Dow Jones · 4d ago
NEXGEL APPOINTS IAN BLACKMAN AS CHIEF FINANCIAL OFFICER
Reuters · 4d ago
Weekly Report: what happened at NXGL last week (0420-0424)?
Weekly Report · 4d ago
NexGel Receives Nasdaq Deficiency Notice Over Bid Price
TipRanks · 04/24 22:33
NexGel gets Nasdaq notice for failing $1 minimum bid price rule
PUBT · 04/24 21:15
NexGel Bets Big With Transformational Acquisition And Financing
TipRanks · 04/23 00:02
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 04/22 21:05
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition
Seeking Alpha · 04/21 23:31
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/21 21:05
NEXGEL GAAP EPS of -$0.38 misses by $0.32, revenue of $11.42M misses by $5.46M
Seeking Alpha · 04/21 20:52
NEXGEL Secures Strategic Financing and Regenerative Portfolio License
TipRanks · 04/21 20:44
NexGel And Celularity Enter Amendment No. 1 To License Agreement On April 17, 2026; Co To Pay Celularity $13.3M Including $8.3M Cash And $5M Convertible Note
Benzinga · 04/21 20:39
NEXGEL INC - CO AND CELULARITY ENTER AMENDMENT NO. 1 TO LICENSE AGREEMENT ON APRIL 17, 2026 - SEC FILING
Reuters · 04/21 20:23
NEXGEL INC - CO TO PAY CELULARITY $13.3 MLN INCLUDING $8.3 MLN CASH AND $5 MLN CONVERTIBLE NOTE - SEC FILING
Reuters · 04/21 20:23
More
Webull provides a variety of real-time NXGLW stock news. You can receive the latest news about Nexgel Inc Wt Exp 120126 through multiple platforms. This information may help you make smarter investment decisions.
About NXGLW
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. It also specializes in eye and eyelash consumer products.